TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA · XNYSCIK 818686fmd_03PSJXMXXNVJX0R7PADE005SZ3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 76 periods
Latest annual · FY2025
Millions- Total revenues
- 17,258
- Gross profit
- 8,938
- Operating income
- 2,157
- Net income
- 1,410
- Free cash flow
- 1,148
Latest quarter · Q3 FY2026
Millions- Total revenues
- 4,395
- Gross profit
- 2,440
- Operating income
- 714
- Net income
- 233
- Free cash flow
- 121
Daily close · TEVAIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions43.22 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +5.0%
- Revenue, 5 yearsFY2020 to FY2025
- +0.7%
- Net income, 5 yearsFY2020 to FY2025
- n/m
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $17.3 billion | $16.5 billion | +4.3% | 10-K 2026-02-03 · proof |
| Gross profit | $8.9 billion | $8.1 billion | +10.8% | 10-K 2026-02-03 · proof |
| Operating income | $2.2 billion | -$303 million | 10-K 2026-02-03 · proof | |
| Net income | $1.4 billion | -$1.6 billion | 10-K 2026-02-03 · proof | |
| Cash from operating activities | $1.6 billion | $1.2 billion | +32.2% | 10-K 2026-02-03 · proof |
| Free cash flow | $1.1 billion | $749 million | +53.3% | 10-K 2026-02-03 · proof |
| Total assets | $40.7 billion | $39.3 billion | +3.6% | 10-K 2026-02-03 · proof |
| Total liabilities | $32.8 billion | $33.6 billion | -2.3% | 10-K 2026-02-03 · proof |
| Cash and cash equivalents | $3.6 billion | $3.3 billion | +7.8% | 10-K 2026-02-03 · proof |
- What was TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s revenue in fiscal 2025?
- TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported revenue of $17.3 billion for fiscal 2025 (the year ended Dec 31, 2025), against $16.5 billion the year before (+4.3%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What was TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s gross profit in fiscal 2025?
- TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported gross profit of $8.9 billion for fiscal 2025 (the year ended Dec 31, 2025), against $8.1 billion the year before (+10.8%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What was TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s operating income in fiscal 2025?
- TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported operating income of $2.2 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$303 million the year before. Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What was TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s net income in fiscal 2025?
- TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported net income of $1.4 billion for fiscal 2025 (the year ended Dec 31, 2025), against -$1.6 billion the year before. Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What was TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s cash from operating activities in fiscal 2025?
- TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported cash from operating activities of $1.6 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.2 billion the year before (+32.2%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What was TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s free cash flow in fiscal 2025?
- TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported free cash flow of $1.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $749 million the year before (+53.3%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What are TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s total assets?
- As of Dec 31, 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported total assets of $40.7 billion, against $39.3 billion a year earlier (+3.6%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What are TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s total liabilities?
- As of Dec 31, 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported total liabilities of $32.8 billion, against $33.6 billion a year earlier (-2.3%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
- What are TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s cash and cash equivalents?
- As of Dec 31, 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported cash and cash equivalents of $3.6 billion, against $3.3 billion a year earlier (+7.8%). Source: the 10-K filed with the SEC on Feb 3, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:TEVA&period_type=annual&limit=5"Information only, not investment advice.